News

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended September 30, 2021.

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will be presenting an ePoster at the 2021 Pancreas Club Annual Meeting being held virtually on November 11-12, 2021.

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its novel therapy platform, RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion), will be highlighted during a presentation by expert panelist, Dr. Ripal Gandhi, at the Miami Cancer Institute’s New…

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath Delivery System. The RenovoCath Delivery System is…

RenovoRx, Inc., a biopharmaceutical company and innovator in targeted cancer therapy, today announced the pricing of its underwritten initial public offering of 1,850,000 units at a public offering price per unit of $9.00.  Each unit consists of one share of…

RenovoRx, a biopharmaceutical company and innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office issued U.S. Patent No. 11,052,224. This new patent extends the Company’s extensive coverage of its novel RenovoRx therapeutic Trans-Arterial Micro-Perfusion (RenovoTAMP™)…

A new treatment for pancreatic cancer is being tested out in clinical trials in several states, and one North Carolina doctor called it “groundbreaking.”

A Lakewood Ranch retiree is one of the first patients in the country to receive an experimental treatment for pancreatic cancer through a trial offered at Sarasota Memorial Hospital. Vince Scully, 74, was diagnosed with Stage III pancreatic cancer in…

RenovoRx, an innovator in targeted cancer therapy, today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment. In one presentation, preliminary data from the ongoing Phase III…

RenovoRx, an innovator in targeted cancer therapy, today announced it has reached an important milestone with continued momentum and the enrollment of the 100th patient in its phase III TIGeR-PaC clinical trial. This trial utilizes the company’s proprietary Trans-Arterial Micro-Perfusion…

Last year, a 74-year old woman was diagnosed with inoperable pancreatic cancer. Her family turned to Miami Cancer Institute in their search for treatment options. Since her diagnosis, she became part of the TIGeR-PaC clinical trial, and is now in a maintenance phase and says…

RenovoRx, an innovator in targeted cancer therapy, today announced it won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020. The peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma honors companies demonstrating innovative solutions, technologies, and services that could make the…

RenovoRx, an innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office has allowed U.S. Patent Application number 15,807,011. This new patent will broadly cover RenovoRx’s unique therapeutic method called Trans-Arterial Micro-Perfusion (TAMPTM) which is designed…

RenovoRx, an innovator in targeted cancer therapy, today announced the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for treating bile duct cancer—- also known as cholangiocarcinoma— with intra-arterial gemcitabine. The Company’s proprietary FDA cleared…

RenovoRx, Inc., an innovator in targeted cancer therapy, and Parexel Biotech, a division of Parexel, one of the world’s leading global clinical research organizations (CROs) focused on accelerating the development and delivery of innovative new therapies to improve world health, today…

RenovoRx, an innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office issued U.S. Patent 10,512,761 covering kits for delivery of chemotherapeutic agents within the body. These kits may be used for the localized and specific…

An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies. Reviews how recent advances in surgery, radiation therapy, ablative options, and endovascular therapies have brought promise and hope to patients with…

70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling…

Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer…

RenovoRx, Inc., a medical technology company developing an innovative catheter-based approach to treating pancreatic cancer, today announced a $10 million financing round of which the company closed $7 million in an initial tranche. The round is led by Boston Scientific…

RenovoRx, a Silicon Valley-based medical device company, announced today that two teams of researchers treating patients with advanced non-metastatic pancreatic tumors reported beneficial effects including lengthened survival rates when using the company’s RenovoCath™ with targeted chemotherapy. The researchers also observed…

Aim: A dose-escalation study of Gemcitabine for treatment of unresectable pancreatic cancer, using a targeted intra-arterial delivery catheter (RenovoCath™). Methods: 20 patients at two centers were enrolled with a fourstage dose escalation of gemcitabine up to 1000 mg/m2. Enzyme markers,…

RenovoRx, manufacturer of the RenovoCath adjustable dual-balloon infusion catheter, today, announced it has received FDA 510(k) clearance to expand its indications for use to include the ‘delivery of chemotherapeutics’. The RenovoCath device isolates segments of the peripheral vasculature, allowing physicians…

RenovoRx, a leading developer of innovative solutions for targeted therapy today announced that the company has received two new device patents, Devices Methods and Kits for Delivery of Therapeutic Materials to a Target Artery (U.S. Patent No. 9,457,171 and U.S.…

El Camino Hospital in Mountain View, California has enrolled the first patient in a safety study using the RenovoCath™, a new catheter that is being introduced for targeted delivery of fluids to selected sites in the peripheral vascular system. The…

RenovoRx, a leading developer of innovative solutions for targeted delivery of fluids to selected sites in the vascular system,today announced that it has achieved ISO 13485:2003 certification, an internationally recognized quality standard for medical devices. BSI (the British Standards Institution)…

RenovoRx, a leading developer of innovative solutions for targeted delivery of fluids to selected sites in the vascular system, today announced the company has received FDA 510(k) clearance of its flagship product, the RenovoCath RC120 catheter.

RenovoRx, a leading developer of innovative solutions for the isolation of blood flow and delivery of fluids to selected sites in the vascular system, today announced that the United States Patent and Trademark Office has issued U.S. patent application number…

RenovoRx Inc. today announces that its Board of Directors has appointed Shaun R. Bagai as Chief Executive Officer and member of the Board of Directors effective June 16, 2014.

RenovoRx is thrilled to announce that Klaus W. Hambuechen, Laurence Marton, MD, and Una Ryan, PhD, have joined Marta Gaia Zanchi, PhD, CEO and Dr. Ramtin Agah, MD, CMO on the Company’s Board of Directors.